甲磺酸伊马替尼治疗43例慢性粒细胞白血病进展期患者的疗效观察

摘要

目的:探讨甲磺酸伊马替尼(STI571,格列卫)治疗慢性粒细胞白血病(CML)进展期(即加速期、急变期)患者的临床疗效.方法:43例疾病进展期CML患者口服格列卫治疗,评价其血液学、细胞遗传学及分子遗传学疗效.结果:43例患者的完全血液学反应(CHR)率、完全细胞遗传学反应(CCyR)率和完全分子遗传学反应(CMR)率分别为44.2％、30.0％和21.9％,观察期内总病死率为25.6％,均于12个月内死亡,不同年龄(≤25岁,＞25岁)患者之间病死率有统计学意义(P＜0.05).结论:格列卫对慢性粒细胞白血病进展期患者有一定的疗效,但耐药现象较普遍,年轻患者的预后可能较差.%Objective: To investigate the effects of imatinib mesylate in treatment of advanced chronic myelogenous leukemia. Methods: To observe the hematologic, cytogenetic and molecular genetic effect of Gleevic in treatment of 43 cases with advanced chronic myelogenous leukemia. Results; The complete hematologic response, complete cytogenetic response and complete molecular genetic response was 44. 2% , 30. 0% and 21. 9% , respectively. Total mortality during observation was 25.6% , and those were dead in 12 months. There was statistically difference in different ages ( ≤25 yeas and >25 years). Conclusions; Gleevic had effects in patients with advanced chronic myelogenous leukemia, but the drug resistance is common, and young patients might have bad prognosis.